Gilead Sciences, Inc. Announces New Real-World Data Further Support The Use Of Veklury For People Hospitalized With COVID-19
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences, Inc. (NASDAQ:GILD) announced new real-world data supporting the use of Veklury (remdesivir) for hospitalized COVID-19 patients, presented at the 31st Conference on Retroviruses and Opportunistic Infections. The data show Veklury's association with reduced long-COVID symptoms and mortality, especially among immunocompromised patients. One study highlighted a 10% lower risk of post-COVID conditions with Veklury use. Another analysis from the Omicron era indicated a 25% lower mortality risk among immunocompromised patients treated with Veklury. Additionally, a combination of Veklury and dexamethasone was associated with significantly lower mortality compared to dexamethasone alone, across various oxygen requirements.
March 05, 2024 | 9:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences, Inc. (GILD) reveals positive real-world data on Veklury's efficacy in reducing long-COVID symptoms and mortality among hospitalized COVID-19 patients, including the immunocompromised.
The announcement of positive real-world data on Veklury's efficacy in treating COVID-19, especially among immunocompromised patients, is likely to bolster investor confidence in Gilead Sciences. The data supports Veklury's role as a standard of care for hospitalized COVID-19 patients, potentially leading to increased usage and sales. This could have a positive short-term impact on GILD's stock price as it reinforces the company's position in the COVID-19 treatment market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100